Summary Slide.png (117.66 kB)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

media

posted on 2021-04-15, 13:27 authored by Adis journals on behalf of, Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge, Robert J. Fox

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Anti-JCV antibody negative Magnetic resonance imaging Natalizumab No evidence of disease activity Relapsing-remitting multiple sclerosis

Licence

CC BY-NC 4.0

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

History

Usage metrics

Categories

Keywords

Licence

Exports